Genital Herpes - Market Insights, Epidemiology and Market Forecast - 2027

  • ID: 4564661
  • Drug Pipelines
  • Region: Global
  • 130 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • AiCuris
  • Genocea Biosciences
  • GlaxoSmithKline
  • Maruho
  • Novartis
  • Vical
  • MORE
‘Genital Herpes- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Genital Herpes in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Genital Herpes from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Genital Herpes- Disease Understanding and Treatment Algorithm

The Genital Herpes market report gives the thorough understanding of the disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Genital Herpes in the US, Europe, and Japan.

Genital Herpes Epidemiology

The Genital Herpes epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, gender-specific prevalent cases and total diagnosed cases) scenario of Genital Herpes in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to this research, the total number of prevalent population of Genital Herpes was found to be 81,556,334 in the year 2016 in 7MM.

Genital Herpes Drug Chapters

This segment of the Genital Herpes report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The current therapeutic market is dominated by the use of anti-viral therapies including Acyclovir, Famciclovir and Valacyclovir. Since these drugs have gone off patent the therapeutic market is flooded with their generic versions. Detailed chapter for upcoming therapies like Pritelivir (AiCuris.), two therapeutic vaccines VCL-HBOL (Vical) and GEN-003 (Genocea Biosciences) and M5210B (Maruho) have been covered in the report.

Genital Herpes Market Outlook

The Genital Herpes market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Genital Herpes in 7MM was found to be USD 883 million in 2016.

Genital Herpes Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Genital Herpes Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Genital Herpes Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Genital Herpes Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits:
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Genital Herpes market
  • Organize sales and marketing efforts by identifying the best opportunities for Genital Herpes market
  • To understand the future market competition in the Genital Herpes market
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AiCuris
  • Genocea Biosciences
  • GlaxoSmithKline
  • Maruho
  • Novartis
  • Vical
  • MORE
1. Key Insights

2. Genital Herpes Market Overview at a Glance
2.1. Market Share (%) Distribution of Genital Herpes in 2017
2.2. Market Share (%) Distribution of Genital Herpes in 2027

3. Disease Background and Overview: Genital Herpes
3.1. Introduction
3.2. Pathophysiology
3.3. Causes
3.4. Risk factors
3.5. Complications
3.6. Signs and Symptoms
3.7. Clinical Manifestations
3.8. Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Disease Definition
4.3. Population and Forecast Parameters
4.4. 7MM Prevalent Population of Genital Herpes

5. Country Wise-Epidemiology of Genital Herpes
5.1. United States
5.1.1. Prevalent Population of Genital Herpes
5.1.2. Gender Specific Prevalent Population of Genital Herpes
5.1.3. Total Diagnosed Cases of Genital Herpes
5.2. Germany
5.2.1. Prevalent Population of Genital Herpes
5.2.2. Gender Specific Prevalent Population of Genital Herpes
5.2.3. Total Diagnosed Cases of Genital Herpes
5.3. France
5.3.1. Prevalent Population of Genital Herpes
5.3.2. Gender Specific Prevalent Population of Genital Herpes
5.3.3. Total Diagnosed Cases of Genital Herpes
5.4. United Kingdom
5.4.1. Prevalent Population of Genital Herpes
5.4.2. Gender Specific Prevalent Population of Genital Herpes
5.4.3. Total Diagnosed Cases of Genital Herpes
5.5. Italy
5.5.1. Prevalent Population of Genital Herpes
5.5.2. Gender Specific Prevalent Population of Genital Herpes
5.5.3. Diagnosed Cases of Genital Herpes
5.6. Spain
5.6.1. Prevalent Population of Genital Herpes
5.6.2. Gender Specific Prevalent Population of Genital Herpes
5.6.3. Diagnosed Cases of Genital Herpes
5.7. Japan
5.7.1. Prevalent Population of Genital Herpes
5.7.2. Gender Specific Prevalent Population of Genital Herpes
5.7.3. Diagnosed Cases of Genital Herpes

6. Current Treatment and Medical Practices
6.1. Treatment of drug-resistant Genital Herpes Simplex Virus Infection in HIV-infected patients
6.2. Treatment Guidelines
6.2.1. Centers for Disease Control and Prevention (CDC): Guidelines for the treatment of Genital Herpes
6.2.2. World Health Organization (WHO): Recommendations for Genital Herpes Simplex Virus
6.2.3. European Guidelines for Management of Genital Herpes

7. Unmet Needs

8. Marketed drugs
8.1. Famvir: Novartis
8.1.1. Drug Description
8.1.2. Other development activities
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Safety and Efficacy
8.1.6. Product Profile
8.2. Valtrex: GlaxoSmithKline
8.2.1. Drug Description
8.2.2. Other development activities
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Safety and Efficacy
8.2.6. Product Profile
8.3. Zovirax: GlaxoSmithKline
8.3.1. Drug Description
8.3.2. Regulatory Milestones
8.3.3. Advantages & Disadvantages
8.3.4. Safety and Efficacy
8.3.5. Product Profile

9. Emerging Drugs
Key Cross Competition
9.1. GEN 003: Genocea Biosciences
9.1.1. Product Description
9.1.2. Other Development Activities
9.1.3. Clinical Development
9.1.4. Clinical Trials Information
9.1.5. Safety and Efficacy
9.1.6. Advantages and Disadvantages
9.1.7. Product Profile
9.2. Pritelivir: AiCuris
9.2.1. Other development activities
9.2.2. Clinical Development
9.2.3. Clinical Trials Information
9.2.4. Safety and Efficacy
9.2.5. Advantages and Disadvantages
9.2.6. Product Profile
9.3. VCL-HB01: Vical
9.3.1. Other Development Activities
9.3.2. Clinical Development
9.3.3. Clinical Trials Information
9.3.4. Safety and Efficacy
9.3.5. Advantages and Disadvantages
9.3.6. Product Profile
9.4. M5210B: Maruho
9.4.1. Product Profile

10. Genital Herpes: 7 Major Market Analysis
10.1. Market Size of Genital Herpes in 7MM
10.2. Genital Herpes Market by Treatment Types
10.3. Emerging Therapies Market of Genital Herpes

11. Market Outlook by Country
11.1. The United States: Market Outlook
11.1.1. United States Market Size
11.1.2. Total Market size of Genital Herpes
11.1.3. Genital Herpes Market by Treatment Types
11.1.4. Market Size by Emerging Therapies
11.2. EU-5 Countries: Market Outlook
11.3. Germany
11.3.1. Total Market size of Genital Herpes
11.3.2. Genital Herpes Market by Treatment Types
11.3.3. Market Size by Emerging Therapies
11.4. France
11.4.1. Total Market size of Genital Herpes
11.4.2. Genital Herpes Market by Treatment Types
11.4.3. Market Size by Emerging Therapies
11.5. United Kingdom
11.5.1. Total Market size of Genital Herpes
11.5.2. Genital Herpes Market by Treatment Types
11.5.3. Market Size by Emerging Therapies
11.6. Spain
11.6.1. Total Market size of Genital Herpes
11.6.2. Genital Herpes Market by Treatment Types
11.6.3. Market Size by Emerging Therapies
11.7. Italy
11.7.1. Total Market size of Genital Herpes
11.7.2. Genital Herpes Market by Treatment Types
11.7.3. Market Size by Emerging Therapies
11.8. Japan: Market Outlook
11.8.1. Total Market size of Genital Herpes
11.8.2. Genital Herpes Market by Treatment Types
11.8.3. Market Size by Emerging Therapies

12. Market Drivers

13. Market Barriers

14. Appendix
14.1. Report Methodology

15. Capabilities

16. Disclaimer

17. About the Publisher

List of Tables
Table 1: Prevalent Population of Genital Herpes in the 7MM (2016-2027)
Table 2: Total Prevalent Population of Genital Herpes in the United States (2016-2027)
Table 3: Gender-Specific Prevalent Population of Genital Herpes in the United States (2016-2027)
Table 4: Total Diagnosed Cases of Genital Herpes in the United States (2016-2027)
Table 5: Total Prevalent Population of Genital Herpes in Germany (2016-2027)
Table 6: Gender-Specific Prevalent Population of Genital Herpes in Germany (2016-2027)
Table 7: Total Diagnosed Cases of Genital Herpes in the Germany (2016-2027)
Table 8: Prevalent Population of Genital Herpes in France (2016-2027)
Table 9: Gender-Specific Prevalent Population of Genital Herpes in France (2016-2027)
Table 10: Total Diagnosed Cases of Genital Herpes in the France (2016-2027)
Table 11: Prevalent Population of Genital Herpes in the United Kingdom (2016-2027)
Table 12: Gender-Specific Prevalent Population of Genital Herpes in the United Kingdom (2016-2027)
Table 13: Total Diagnosed Cases of Genital Herpes in the United Kingdom (2016-2027)
Table 14: Prevalent Population of Genital Herpes in Italy (2016-2027)
Table 15: Gender-Specific Prevalent Population of Genital Herpes in Italy (2016-2027)
Table 16: Diagnosed Cases of Genital Herpes in Italy (2016-2027)
Table 17: Prevalent Population of Genital Herpes in Spain (2016-2027)
Table 18: Gender-Specific Prevalent Population of Genital Herpes in Spain (2016-2027)
Table 19: Diagnosed Cases of Genital Herpes in Spain (2016-2027)
Table 20: Prevalent Population of Genital Herpes in Japan (2016-2027)
Table 21: Gender-Specific Prevalent Population of Genital Herpes in Japan (2016-2027)
Table 22: Diagnosed Cases of Genital Herpes in Japan (2016-2027)
Table 23: Dosage of Aciclovir for Genital Herpes
Table 24: Efficacy of Acyclovir, Valaciclovir, and Famciclovir in the treatment of genital HSV Disease
Table 25: Antiviral Agents for treatment of drug-resistant Genital Herpes Simplex Virus Infection in HIV-Infected patients
Table 26: Recommended Regimens for First Clinical Episode of Genital Herpes
Table 27: Comparison of emerging drugs under development (Phase III)
Table 28: GEN-003,Clinical Trial Description, 2018
Table 29: Pritelivir, Clinical Trial Description, 2018
Table 30: VCL-HB01, Clinical Trial Description, 2018
Table 31: 7 Major Market Size of Genital Herpes in USD Million (2016-2027)
Table 32: 7MM Genital Herpes Market by Treatment types in USD Million (2016-2027)
Table 33: 7MM Emerging Therapies market size of Genital Herpes in USD Million (2016-2027)
Table 34: 7 Major Market Size of Genital Herpes in USD Million (2016-2027)
Table 35: The U.S. Genital Herpes Market by Treatment types in USD Million (2016-2027)
Table 36: Emerging Therapies market size of Genital Herpes in USD Million (2016-2027)
Table 37: Market Size of Genital Herpes in Germany, in USD Million (2016-2027)
Table 38: Genital Herpes Market by Treatment types in Germany, in USD Million (2016-2027)
Table 39: Emerging Therapies market of Genital Herpes in Germany, in USD Million (2016-2027)
Table 40: Market Size of Genital Herpes in France, in USD Million (2016-2027)
Table 41: Genital Herpes Market by Treatment types in France, in USD Million (2016-2027)
Table 42: Emerging Therapies market of Genital Herpes in France, in USD Million (2016-2027)
Table 43: Market Size of Genital Herpes in the UK, in USD Million (2016-2027)
Table 44: Genital Herpes Market by Treatment types in the UK, in USD Million (2016-2027)
Table 45: Emerging Therapies market of Genital Herpes in the UK, in USD Million (2016-2027)
Table 46: Market Size of Genital Herpes in Spain, in USD Million (2016-2027)
Table 47: Genital Herpes Market by Treatment types in Spain, in USD Million (2016-2027)
Table 48: Emerging Therapies market of Genital Herpes in Spain, in USD Million (2016-2027)
Table 49: Market Size of Genital Herpes in Italy, in USD Million (2016-2027)
Table 50: Genital Herpes Market by Treatment types in Italy, in USD Million (2016-2027)
Table 51: Emerging Therapies market of Genital Herpes in Italy, in USD Million (2016-2027)
Table 52: Market Size of Genital Herpes in Japan, in USD Million (2016-2027)
Table 53: Genital Herpes Market by Treatment types in Japan, in USD Million (2016-2027)
Table 54: Emerging Therapies market of Genital Herpes in Japan, in USD Million (2016-2027)

List of Figures
Figure 1: Keratin Proteins and EB Simplex involved in Pathophysiology of Herpes Simplex Virus
Figure 2: Signs and Symptoms of Genital Herpes
Figure 3: Prevalent Population of Genital Herpes in the 7MM (2016-2027)
Figure 4: Total Prevalent Population of Genital Herpes in the United States (2016-2027)
Figure 5: Gender-Specific Prevalent Population of Genital Herpes in the United States (2016-2027)
Figure 6: Total Diagnosed Cases of Genital Herpes in the United States (2016-2027)
Figure 7: Total Prevalent Population of Genital Herpes in Germany (2016-2027)
Figure 8: Gender-Specific Prevalent Population of Genital Herpes in Germany (2016-2027)
Figure 9: Total Diagnosed Cases of Genital Herpes in the Germany (2016-2027)
Figure 10: Prevalent Population of Genital Herpes in France (2016-2027)
Figure 11: Gender-Specific Prevalent Population of Genital Herpes in France (2016-2027)
Figure 12: Total Diagnosed Cases of Genital Herpes in France (2016-2027)
Figure 13: Prevalent Population of Genital Herpes in the United Kingdom (2016-2027)
Figure 14: Gender-Specific Prevalent Population of Genital Herpes in the United Kingdom (2016-2027)
Figure 15: Total Diagnosed Cases of Genital Herpes in the United Kingdom (2016-2027)
Figure 16: Prevalent Population of Genital Herpes in Italy (2016-2027)
Figure 17: Gender-Specific Prevalent Population of Genital Herpes in Italy (2016-2027)
Figure 18: Diagnosed Cases of Genital Herpes in Italy (2016-2027)
Figure 19: Prevalent Population of Genital Herpes in Spain (2016-2027)
Figure 20: Gender-Specific Prevalent Population of Genital Herpes in Spain (2016-2027)
Figure 21: Diagnosed Cases of Genital Herpes in Spain (2016-2027)
Figure 22: Prevalent Population of Genital Herpes in Japan (2016-2027)
Figure 23: Gender-Specific Prevalent Population of Genital Herpes in Japan (2016-2027)
Figure 24: Diagnosed Cases of Genital Herpes in Japan (2016-2027)
Figure 25: Treatment Algorithm of Genital Herpes
Figure 26 : Activation of Acyclovir
Figure 27: Mechanisms of action of Anti-Herpes Simplex Virus Antiviral drugs
Figure 28: Unmet Needs of Genital Herpes
Figure 29: 7 Major Market Size of Genital Herpes in USD Million (2016-2027)
Figure 30: 7MM Genital Herpes Market by Treatment types in USD Million (2016-2027)
Figure 31: 7MM Emerging Therapies market size of Genital Herpes in USD Million (2016-2027)
Figure 32: Market Size of Genital Herpes in the United States, USD Million (2016-2027)
Figure 33: The U.S. Genital Herpes Market by Treatment types in USD Million (2016-2027)
Figure 34: The U.S. Emerging Therapies market size of Genital Herpes in USD Million (2016-2027)
Figure 35: Market Size of Genital Herpes in Germany, USD Million (2016-2027)
Figure 36: Genital Herpes Market by Treatment types in Germany, in USD Million (2016-2027)
Figure 37: Emerging Therapies market of Genital Herpes in Germany, in USD Million (2016-2027)
Figure 38: Market Size of Genital Herpes in France, USD Million (2016-2027)
Figure 39: Genital Herpes Market by Treatment types in France, in USD Million (2016-2027)
Figure 40: Emerging Therapies market of Genital Herpes in France, in USD Million (2016-2027)
Figure 41: Market Size of Genital Herpes in the UK, USD Million (2016-2027)
Figure 42: Genital Herpes Market by Treatment types in the UK, in USD Million (2016-2027)
Figure 43: Emerging Therapies market of Genital Herpes in the UK, in USD Million (2016-2027)
Figure 44: Market Size of Genital Herpes in Spain, USD Million (2016-2027)
Figure 45: Genital Herpes Market by Treatment types in Spain, in USD Million (2016-2027)
Figure 46: Emerging Therapies market of Genital Herpes in Spain, in USD Million (2016-2027)
Figure 47: Market Size of Genital Herpes in Italy, USD Million (2016-2027)
Figure 48: Genital Herpes Market by Treatment types in Italy, in USD Million (2016-2027)
Figure 49: Emerging Therapies market of Genital Herpes in Italy, in USD Million (2016-2027)
Figure 50: Market Size of Genital Herpes in Japan, USD Million (2016-2027)
Figure 51: Genital Herpes Market by Treatment types in Japan, in USD Million (2016-2027)
Figure 52: Emerging Therapies market of Genital Herpes in Japan, in USD Million (2016-2027)
Figure 53: Market Drivers
Figure 54: Market Barriers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Novartis
  • GlaxoSmithKline
  • Genocea Biosciences
  • AiCuris
  • Vical
  • Maruho
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll